Virtual closed meeting for IMI AMR Accelerator partners to get up to speed with the most novel developments from the Consortium's projects. About this Event IMI AMR Cross-Pillar Meeting (invitation only) This was an online meeting where partners were introduced to the AMR Accelerator projects and heard from Dr Timothy Rawson, Honorary Clinical Research Fellow, […]
Join online over 400 international AMR experts for a week-long learning and networking experience. The 4th AMR conference is the one-stop-shop for all AMR stakeholders from industry, SMEs, start-ups, big pharma, academia, clinics, regulatory bodies, investors, public institutions and policy to discuss all relevant challenges of bringing new antimicrobial treatments and diagnostics in the market. […]
This webinar provided an overview of animal infection models commonly used for studies of antibiotics against gram-negative bacteria. The webinar was driven by the COMBINE objective to harmonse and standardise a protocol for a mouse infection model used for efficacy and PKPD studies. The infection model was validated through well-characterised bacterial strains and control compounds […]
December 3, 2020, 3.30PM-4.30PM CET Peter Warn is an experienced antimicrobial discovery scientist and consultant with a long and successful record of working in the anti-infective discovery industry. His expertise goes from antimicrobial development (antibacterial, anti-fungal, anti-parasitic and anti Mtb), including in vitro, and animal models from basic models through to PKPD and assisting in […]
The webinar covered processes for working with aggregated clinical data in the COMBINE consortium and AMR Accelerator. Firstly, the team outlined a set of procedures established for assessing the ethical status of data sets from external organisations. Then, the team described data formats and standards for working with clinical data sets uploaded into the GRIT42 […]
This workshop provided an open discussion forum to identify, propose and prioritise specific challenges, success and risk factors in the development of vaccines against nosocomial AMR pathogens. Participants included experts in clinical vaccine development from industry, academia and regulatory agencies, as well as experts in innovative clinical trial designs. General discussion topics covered pre-existing clinical […]
Each year, World Tuberculosis (TB) Day is commemorated on March 24 to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts to end the global TB epidemic. The date marks the day in 1882 when Dr Robert Koch announced that he had discovered the bacterium that […]
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, this conference will discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
As AMR emerges, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity, led by the UK Medical Research Council (MRC) with support from South Africa (SAMRC), Korea (NRF), France (ANR), and Canada (CIHR) is delivered as part of JPIAMR’s mission to enable global coordination of research. The […]
